The company uses its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs, with ARQ 197 being their primary product. ARQ 197 is an orally administered inhibitor of the c-Met receptor tyrosine kinase and is being evaluated in Phase II clinical trials for various cancer indications. The company has licensed commercial rights to ARQ 197 to Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for different regions of the world. In addition to cancer therapeutics, ArQule also develops targeted therapeutics for rare diseases using novel small molecule drugs in biomarker-defined indications.